Harpoon Therapeutics, Inc. (NASDAQ: HARP) watched its shares barely clear breakeven early Tuesday. The company, a clinical-stage immuno-oncology firm developing novel T cell engagers, today announced the completion of planned patient enrollment in the Phase 1 dose escalation study evaluating the safety, tolerability, and pharmacokinetics of HPN217 in patients with relapsed/refractory multiple myeloma. Additional patients currently in screening will also be allowed to enroll.
“Completing enrollment in the Phase 1 trial of HPN217 is an important step towards potentially bringing this therapy to patients with advanced disease who have progressed after prior treatments," said Chief Medical Officer Luke Walker. “I would like to thank our patients and their caregivers, as well as our clinical partners and dedicated team of employees who have participated in this Phase 1 trial and advanced the development of HPN217.
HPN217 is being evaluated in an ongoing Phase 1, multicenter, open-label dose escalation study designed to evaluate safety, tolerability, pharmacokinetics (PK) and clinical activity in patients with relapsed/refractory multiple myeloma who have had at least three prior systemic treatments, including a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 antibody, including patients with prior exposure to BCMA therapy. Primary objectives are characterization of safety, tolerability, PK and determination of the recommended Phase 2 dose.
HARP shares squeezed higher 0.06 cents or 1%, to 64 cents.
